[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"metabolic-abnormality\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:metabolic-abnormality":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,46],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":28,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100605364","evaluating-metabolic-health-in-people-aged-18-to-60-by-nutrilite-metabolic-health-index-100605364",false,"NCT07161557","Evaluating Metabolic Health in People Aged 18 to 60 by Nutrilite Metabolic Health Index","An Open Observational Study to Evaluate Metabolic Health in People Aged 18 to 60 by Nutrilite Metabolic Health Index","Inclusion Criteria:\n\n* Male and female volunteers, aged 18 to 60, regardless of gender;\n* Not participating in other interventional clinical studies;\n* Have a good understanding of the nature, purpose, benefits obtained, and possible risks and side effects of the study;\n* Willing to comply with all trial requirements and procedures;\n* Sign the informed consent form.\n\nExclusion Criteria:\n\n* In the treatment of gastrointestinal symptoms;\n* Those who are lactose intolerant, allergic to fish and their products;\n* Current suffering from other organic diseases affecting bowel function, such as history of gastrointestinal resection, colon or rectal cancer, inflammatory bowel disease, diabetes, hyperthyroidism or hypothyroidism, Hirschsprung's disease, scleroderma, anorexia nervosa, etc.;\n* Diet control, exercise enhancement, or taking medications that control weight or affect appetite in the past 3 months;\n* Volunteers have any of the following medical history or have been clinically diagnosed with the following diseases that may affect the evaluation of the test results: obvious gastrointestinal disorders, liver, kidney, endocrine, blood, respiratory and cardiovascular diseases;\n* Current or past abuse of alcohol or other illicit drugs, supplements, or OTC prescriptions 3 \u002F 11 Research content Collection of biological samples or information data Evaluation indicators Drugs may cause intestinal dysfunction or affect the evaluation of trial effects;\n* Frequent use of drugs that may affect gastrointestinal function or immune system according to the investigator's judgment.",true,"ALL","18 Years","60 Years",{"count":21,"type":22},200,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate Metabolic Health by fit analysis between calculated Nutrilite Metabolic Health Index and the result of Metabolomics analysis from blood plasma samples in healthy adult participants aged between 18 and 60 years. The main question it aims to answer:\n\n\\- Does the Nutrilite Metabolic Health Index fit well with the result of Metabolomics analysis from blood plasma samples?\n\n200 eligible participants will be enrolled in a single center, one site visit will be made to finish a health questionnaire, a lifestyle questionnaire, a routine physical checkup. Blood samples will be collected for routine blood test (blood sugar, total triglycerides, total cholesterol, low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, uric acid), and for Metabolomics testing.\n\nResearchers will calculate the Nutrilite Metabolic Health Index based on participant data, and do the fit analysis against the result from Metabolomics analysis.",[26,27],"Metabolic Abnormality","Metabolic Disorders",[29,30,31,32],"Diet2Me","Nutrilite Metabolic Health Index","Metabolic health omics model","Metabolomics testing","NOT_YET_RECRUITING","2025-09-07",{"date":36,"type":37},"2025-09-12","ACTUAL",{"date":39,"type":22},"2025-10-09",{"date":41,"type":22},"2026-05-10",{"name":43,"class":44},"Amway (China) R&D Center","INDUSTRY",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":72,"overallStatus":83,"whyStopped":4,"lastUpdateSubmitDate":84,"lastUpdatePostDateStruct":85,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":45},"100580294","high-resolution-pet-ct-specimen-imaging-for-the-perioperative-visualization-of-resection-margins-100580294","NCT06835426","High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins","High-resolution PET-CT Specimen Imaging for the Perioperative Visualization of Resection Margins: an Exploratory Pilot Study","A. Inclusion Criteria:\n\n* able to understand treatment protocol and informed consent form\n* estimated by the investigator to be compliant for study participation\n\n  1\\. Fulfilling all group-specific inclusion criteria:\n* confirmed breast cancer with an indication to undergo breast conserving surgery\n* confirmed prostate cancer with an indication to undergo resective surgeryprostatectomy;\n* confirmed thyroid lesion with an indication to undergo resective surgery;\n* confirmed parathyroid adenoma with an indication to undergo resective surgery;\n* suspected basal cell carcinoma, squamous cell carcinoma or melanoma with an indication to undergo resective surgery;\n* suspected lesion in genitourinary sites (including bladder cancer, renal pelvis and ureter carcinoma, adrenal cortical carcinoma and renal cell carcinoma) with an indication to undergo resective surgery;\n* suspected lesion in the head \\& neck region with an indication to undergo resective surgery;\n* confirmed primary or secondary hepatobiliary cancer with an indication to undergo resective surgery;\n* patients undergoing biopsy after metabolic active lesions were detected on a PET scan.\n* suspected neuro-endocrine malignancies with an indication to undergo resective surgery.\n* suspected brain tumor with an indication to undergo resective surgery.\n* Suspected malignant and benign gastrointestinal lesions with an indication to undergo resective surgery.\n* suspected malignant thoracovascular lesions with an indication to undergo resective surgery\n\nB. Exclusion Criteria:\n\n* general or local contra-indications for resective surgery;\n* in case of FDG-based PET tracers: a blood glucose level over 200 mg\u002FdL on the day of surgery;\n* pregnancy or lactation;\n* participation in other clinical studies with a radiation exposure of more than 1 mSv in the past year.",{"count":54,"type":22},150,"INTERVENTIONAL",[57],"NA","These are patients in whom a benign or malignant tumor was recorded requiring surgery. During that surgery, the surgeon will cut away the tumor as part of the treatment of the disease. In this process, it is important that the tumor is removed correctly and completely. To verify that the correct tissue was completely removed, the tissue is examined microscopically. However, a microscopic analysis takes a relatively long time and the result is not known until a few days after the surgery is completed. If that microscopic analysis should eventually reveal that the tumor was not completely removed, additional treatment is usually necessary. An assessment of the excised tissue during surgery would allow additional tissue to be excised in the same operation if necessary. Thus, in this way, additional treatments can also be avoided. This could lead to shorter treatment time and less emotional strain for the patient, as well as lower costs. To date, however, there are no effective techniques to do this.\n\nPositronEmissionTomography (PET) imaging can be used to image the tumor that needs to be excised. To do this, a tracer must be administered through the blood before the operation. This tracer is a slightly radioactive substance that can be detected by the PET camera even at low concentrations. This technique is already routinely used in the hospital to detect cancer or inflammatory tissue in the body. During this study, however, it's not the intention to look at the tumor while it is still in the patient's body, but rather after it has been cut out of the patient's body by the surgeon. To do this, the piece of tissue cut away will be scanned using a specially designed PET-CT scanner.\n\nThe overall goal of this study is to gain additional knowledge. More specifically, the investigators wish to determine which medical conditions may benefit from high-resolution PET-CT specimen imaging.",[60,61,62,63,64,65,66,67,26,68,69,70,71],"Breast Carcinoma","Prostate Cancer Surgery","Thyroid Cancer","Parathyroid Adenomas","Skin Cancer","Genitourinary Cancer","Head and Neck Cancer","Hepatobiliary Cancers","Neuro Endocrine Tumours","Brain Tumours","Gastro Intestinal Cancer","Thoracoscopic Surgery",[73,74,75,76,77,78,79,80,81,82],"resective surgery","perioperative high-resolution PET-CT specimen imaging","breast cancer","Prostate cancer","thyroid cancer","parathyroid cancer","head and neck cancer","neuro-endocrine malignancies","genitourinary malignacies","thoracovascular malignancies","RECRUITING","2025-02-14",{"date":86,"type":37},"2025-02-19",{"date":88,"type":37},"2023-08-06",{"date":90,"type":22},"2027-06-30",{"name":92,"class":93},"Algemeen Ziekenhuis Maria Middelares","OTHER"]